Pipeline Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer BioSpacePfizer's decision to cut its early-stage cancer asset was due to "strategic business reasons" and not driven by safety or efficacy concerns.PipelineOncologyRead full story pharminent April 24, 2026 (Last updated: April 24, 2026) BioSpace Pfizer’s decision to cut its early-stage cancer asset was due to “strategic business reasons” and not driven by safety or efficacy concerns. PipelineOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Avalyn seeks public debut to support new lung drug formulationsNext: Daiichi Sankyo shares slip after delaying annual earnings report Related Stories Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026 Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026
